Talioti E, Hill R, Gillam D G
Centre for Adult Oral Health, Bart's and the London Queen Mary's School of Medicine and Dentistry, Queen Mary University of London (QMUL), Turner Street, London E1 4NS, UK.
Dental Physical Sciences Unit, Barts and the London School of Medicine and Dentistry, QMUL, London, UK.
ISRN Dent. 2014 Mar 27;2014:865761. doi: 10.1155/2014/865761. eCollection 2014.
Objectives. The aim of the present study was to review the published literature in order to identify relevant studies for inclusion and to determine whether there was any evidence on the clinical effectiveness of selected desensitizing toothpastes, calcium sodium phosphosilicate (CSPS), amorphous calcium phosphate (ACP), nanohydroxyapatite, and casein phosphopeptide-amorphous calcium phosphate (tooth mousse) on reducing dentine hypersensitivity (DH). Materials and Methods. Following a review of 593 papers identified from searching both electronic databases (PUBMED) and hand searching of relevant written journals, only 5 papers were accepted for inclusion. Results. Analysis of the included studies (3 CSPS and 2 ACP) would suggest that there may be some benefit for patients using these products for reducing DH. No direct comparative studies were available to assess all these products under the same conditions neither were there any comparative randomised controlled studies that compared at least two of these products in determining their effectiveness in treating DH. Conclusions. Due to the small number of included studies, there are limited clinical data to support any claims of clinical efficacy of these OTC products. Further studies are therefore required to determine the efficacy of these products in well-controlled RCT studies with a larger sample size.
目的。本研究旨在回顾已发表的文献,以确定纳入的相关研究,并确定是否有证据表明所选脱敏牙膏、磷酸硅钙钠(CSPS)、无定形磷酸钙(ACP)、纳米羟基磷灰石和酪蛋白磷酸肽 - 无定形磷酸钙(牙齿慕斯)在减轻牙本质过敏症(DH)方面的临床有效性。材料与方法。在对通过检索电子数据库(PUBMED)和手工检索相关纸质期刊确定的593篇论文进行回顾后,仅5篇论文被纳入。结果。对纳入研究(3项CSPS研究和2项ACP研究)的分析表明,使用这些产品可能对减轻DH的患者有一定益处。没有直接比较研究可在相同条件下评估所有这些产品,也没有任何比较随机对照研究在确定这些产品治疗DH的有效性时比较至少其中两种产品。结论。由于纳入研究数量较少,支持这些非处方产品临床疗效的临床数据有限。因此,需要进一步研究以在样本量更大的严格控制的随机对照试验研究中确定这些产品的疗效。